How the BOND trial will test prenatal mental health support for congenital heart disease
The BOND trial will test HeartGPS and breastfeeding support for families affected by critical congenital heart disease across 17 US centers.
Pharma & Biotech
Pharma & Biotech
Senhwa’s NT$500m GEM deal sounds like fresh funding, but the structure is more complicated
Senhwa formalises a NT$500 million GEM share purchase pact, but direct funding, dilution and pipeline execution remain the decisive questions.
Pharma & Biotech
What the zemprocitinib enrollment milestone means for Lynk Pharmaceuticals’ late-stage pipeline
Lynk Pharmaceuticals completes Phase III zemprocitinib enrollment as ASAS40 efficacy, long-term safety and China filing tests move closer.
Pharma & Biotech
A US$2.5bn AI drug alliance is taking shape, but what have Insilico and Bora actually agreed?
Insilico Medicine and Bora Pharmaceuticals propose an AI drug alliance worth over US$2.5 billion, but definitive agreements remain pending.
Pharma & Biotech
Multikine is back in Phase 3, but can CEL-SCI turn a striking subgroup signal into approval?
CEL-SCI launches a 212-patient Multikine Phase 3 study, but subgroup validation, funding and regulatory execution remain decisive.
Pharma & Biotech
Tenpoint wants Yuvezzi to open a new UK presbyopia market, but another eye drop filed first
Tenpoint Therapeutics seeks UK authorisation for Yuvezzi, testing whether a dual-agent presbyopia eye drop can build a market beyond the United States.
Pharma & Biotech
Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?
Niagen Bioscience gains U.S. and EU rare-disease designations for NB4168, but human trials and proof of efficacy still lie ahead.
Pharma & Biotech
Can engineered Treg therapy scale? Cellares and Sonoma begin a crucial manufacturing test
Cellares will automate SBT-77-7101 manufacturing as Sonoma Biotherapeutics prepares its CAR-Treg program for larger clinical trials.
Pharma & Biotech
Quoin Pharmaceuticals clears FDA hurdle for QRX003 peeling skin syndrome trial
Quoin Pharmaceuticals Ltd. has received U.S. Food and Drug Administration clearance for an investigational new drug application covering QRX003 in generalized inflammatory peeling skin syndrome, allowing the Nasdaq-listed rare-disease developer to initiate a Phase 2 trial in the second half of 2026. The study will enroll six to eight pediatric and adult participants in the
Pharma & Biotech
Takeda’s $30m Indonesia plasma bet starts with donors, not the drug factory
Takeda plans a $30 million Indonesia plasma network as local manufacturing stays under review. See what the deal changes for medicine access.